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In addition to flow cytometry we want to show how modern
microscopes help to perform a variety of routine and specialty
applications.
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Cancer cells display altered methylation signatures distin-
guishing them from normal cells. Originating from all tissues
and cells of the body cell-free DNA (cfDNA) including aberrantly
methylated DNA reflect epigenetic aberrations occurs not only
in tumor cells but also in tumor microenvironment. Actually,
aberrantly methylated cfDNA has proved to be a promising
biomarker for noninvasive detection of cancer with several
clinically-certified tests (Epi-pro Colon, Epi-pro Lung, Colo-
guard). However only one test (Epi-pro Colon) uses blood
plasma – the most convenient source of cfDNA. Input of tissue
and age specific methylation along with unidentified reasons lead
to the presence of molecules with every conceivable cytosine-
methylation patterns which decrease probability of tumor DNA
identification. Among numerous variants of cfDNA methylation
patterns only few reflect cancer related changes. To identify those
tumor-specific profiles single nucleotide resolution of methylated
cytosine locations in the individual circulating DNA molecules is
obviously required.
We performed target bisulfite sequencing of potential prostate
cancer (PC) cfDNA markers (GSTP1; RNF219) isolated from blood
plasma of 18 healthy donors (HD), 17 benign hyperplasia (BPH)
and 20 PC patients using MiSeq platform (Illumina). RNF219 gene
was shown to have high diagnostic potential in our previous
comparative study of cfDNA from HD, PC and BHP patients using
HCGI12k microarrays (Cortese, et al., 2012). GSTP1 is a common
pathological DNA methylation event in PC and is most widely
studied and promising methylation marker in the cfDNA of PC
patients (Wu, et al., 2011).
Selected loci were amplified after bisulfite conversion (Zymo
Research) of cfDNA with methyl-independent barcoded primers
and sequenced with coverage ranging from 23509 to 143953.
Identification of CpG methylation status in DNA fragments was
performedwith the BiQ Analyzer HT Software. All statistical anal-
ysis was performed using R Statistical Software (version 3.1.1) To
reveal diagnostically significant differences, several approaches
to data analysis were used. Conventional approach is a prediction
of patient’s diagnosis based on differences in methylation level
of CpG-sites. Another approach used in this study relies on
discrimination of cancer-related correlation between methylation
statuses of CpG-sites within individual molecules of cfDNA –
Intramolecular Correlation of Methylation Statuses (ICoMS).
Study population was randomly subsampled into training and
test cohorts. The logit regression model based on methylation
level of CpG-sites achieved an area under the ROC curve (AUC)
exceeding 0.94 in both cohorts for GSTP1 gene and 0.81 – for
RNF219 gene. A novel approach to identify diagnostic significance
of cfDNA methylation was based on comparison of correlation
matrices (pairwise phi coefficient between methylation statuses
of CpG sites) for HD, BHP and PC groups. Binomial regression
models with LASSO penalization were used to predict patient’s
diagnosis. ROC curves for fitted models show AUC, specificity
and sensitivity as 0.99, 100% and 92% for GSTP1 gene and 0.99,
100% and 90% for RNF219 (test cohort).
The ICoMS approach estimates diagnostic value of target
genes and reveals cancer-related cytosine methylation. That
could potentially input in gene expression, identify the features
of tumor physiology and on a par with conventional approaches
provide helpful information for rational design of noninvasive,
methylation-specific cfDNA-based diagnostics for PC.
Moreover, the planned further evaluation of relationship
between the revealed correlations associated with cancer
and tumor biology could increase the basic knowledge of
carcinogenesis.
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Background: Breast cancer ranks the first among female onco-
logical diseases and ranks the second after lung cancer among
causes of cancer related deaths. Use of contemporary anticancer
drugs significantly enhanced possibilities of cancer therapy.
However, most of medicines against cancer have such disadvan-
tages as toxicity, narrowness of therapeutic action, and
emergence of drug resistance. Recently, an approach based on
potential of dendritic cells (DCs) to induce formation of cytotoxic
T-cell immune response against cancer cells is widely used. Prim-
ing of dendritic cells by DNA-constructs encoding immunogenic
epitopes of tumor antigens is regarded as a rather promising
approach to design cancer vaccines. The aim of this study is to
construct, obtain and study expression in eukaryotic cells of
recombinant plasmid – candidate DNA-vaccines inducing T-cell
immune response against breast cancer.
Materials and methods: Using the PolyCTLDesigner software,
DNA-vaccine construct was made encoding polyepitope T-cell
immunogen BC-A*0201. Gene encoding target immunogen was
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